HEMOSTATIC FIBROUS MATERIAL

• US 20120004636A1
• Filed: 07/01/2011
• Published: 01/05/2012
• Est. Priority Date: 07/02/2010
• Status: Abandoned Application

• Current Assignee: Teleflex Life Sciences II LLC
• Original Assignee: Teleflex Life Sciences II LLC
• Inventors: Lo, Denny
• Application Number:
  US13/175,380
• Publication Number:
  US 20120004636A1
• Time in Patent Office: Days
• US Class Current: 604/500
• CPC Class Codes: A61F 13/00 Bandages or dressings radioactive dressings A61N5/1029; Absorbent pads
• CPC Class Codes: A61F 2013/00463 haemostatic
• CPC Class Codes: A61K 33/06 Aluminium, calcium or magnesium; Compounds thereof , e.g. clay
• CPC Class Codes: A61L 15/42 Use of materials characterised by their function or physical properties liquid bandages A61L26/00
• CPC Class Codes: A61L 15/44 Medicaments
• CPC Class Codes: A61L 2300/418 Agents promoting blood coagulation, blood-clotting agents, embolising agents
• CPC Class Codes: A61L 2400/04 Materials for stopping bleeding
• CPC Class Codes: A61P 7/04 Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents

Abstract

This disclosure relates to devices for promoting the clotting of blood in human beings or animals, or hemostatic devices. These devices may comprise a fibrous material or materials comprising one or more fibers such as a gauze or a cloth. Some of the fibers in these materials or devices may comprise a macromolecular material and a hemostatic hemostatic additive material such as kaolin or another clay.

Claims

1. A method of promoting blood clotting comprising:

opening a sterilized packaging containing a hemostatic device; and

placing the hemostatic device in direct contact with a bleeding area of a human being or animal;

wherein the hemostatic device comprises a fibrous material comprising a macromolecular host material and a clay additive material; and

wherein the fibrous material is stable in the presence of blood.

2. The method of claim 1, wherein the clay additive material comprises kaolin.

3. The method of claim 1, wherein the clay additive is uncoated.

4. The method of claim 1, wherein the macromolecular host material comprises rayon or a polyester.

5. A device for promoting the clotting of blood comprising:

a fabric substrate comprising a fibrous material and a sterilized packaging

wherein the fibrous material comprises;

a host comprising a polymer, and a hemostatic additive comprising kaolin;

wherein the fibrous material comprises a plurality of individual fibers, each fiber having an interior and a surface;

wherein the kaolin is dispersed in the host throughout the interior and affixed to the host at the surface;

wherein the surface has a greater loading level of kaolin than the interior; and

wherein the substrate is contained within the sterilized packaging.

6. The device of claim 5, wherein the polymer comprises rayon.

7. The device of claim 5, the plurality of fibers is substantially stable in the presence of blood.

8. The device of claim 5, wherein the fabric substrate has a length of about 1 inch to about 10 inches and a width of about 2 inches to about 5 inches.

9. The device of claim 5, wherein the fabric substrate has a length of about 0.5 yards to about 20 yards and a width of about 1 inch to about 10 inches.

10. A blood clotting device comprising:

a sterile gauze substrate comprising a blend of a first fiber comprising a cellulosic material and a second fiber comprising a synthetic polymer; and

wherein at least one of the first fiber and the second fiber comprises an inorganic hemostatic additive having hemostatic properties.

11. The device of claim 10, wherein the cellulosic material comprises rayon and the synthetic polymer comprises a polyester.

12. The device of claim 10, wherein devices is configured so that if the first fiber or the second fiber comes in contact with blood, substantially all of the inorganic hemostatic additive is retained in or on the first fiber or the second fiber for at least about 10 minutes of contact with blood.

13. The device of claim 10, wherein the second fiber comprises the inorganic hemostatic additive.

14. The device of claim 10, wherein the first fiber comprises the inorganic hemostatic additive.

15. The device of claim 10, wherein the inorganic hemostatic additive is about 1% to about 20% of the second fiber by weight.

16. The device of claim 10, wherein the first fiber has a diameter of about 0.1 μ

m to about 100 μ

m.

17. The device of claim 10, wherein at least one of the first fiber and the second fiber comprises a therapeutically active agent.

18. The device of claim 10, further comprising a release agent disposed on the gauze substrate.

19. The device of claim 10, wherein the device is vacuum packed in a sterile or sterilized packaging.

20. The device of claim 10, wherein the first fiber is rayon and the inorganic hemostatic additive is kaolin.